Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oosterkamp

Showing results (111-120 of 127) with videos related to

Pageof 13
Sort By:
NPJ Breast Cancer|January 22, 2025
Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionalityNoor A M Bakker, Hannah Garner, Ewald van Dyk, et al.
Journal of Sex & Marital Therapy|November 26, 2019
Sexual Health Needs: How Do Breast Cancer Patients and Their Partners Want Information?L F Albers, G F Van Ek, E M Krouwel, et al.
Breast Care (Basel, Switzerland)|January 28, 2022
Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01)Annelot G J van Rossum, Ingrid A M Mandjes, Erik van Werkhoven, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2018
Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)A G J van Rossum, M Kok, E van Werkhoven, et al.
Oncotarget|January 27, 2018
Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapyAnnelot G J van Rossum, Marleen Kok, Danielle McCool, et al.
Cell Reports|April 6, 2022
FER regulates endosomal recycling and is a predictor for adjuvant taxane benefit in breast cancerSandra Tavares, Nalan Liv, Milena Pasolli, et al.
Ultramicroscopy|November 19, 2011
Interlaboratory round robin on cantilever calibration for AFM force spectroscopyJoost te Riet, Allard J Katan, Christian Rankl, et al.
Journal of Bacteriology|July 12, 2011
Genome sequences of Alicycliphilus denitrificans strains BC and K601TMargreet J Oosterkamp, Teun Veuskens, Caroline M Plugge, et al.
Cancer Research|January 15, 2016
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB TrialLale Erdem-Eraslan, Martin J van den Bent, Youri Hoogstrate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2025
Ribociclib-letrozole combination as an alternative for neoadjuvant chemotherapy in selected post-menopausal patients with luminal breast cancer (BOOG 2017-01)Anne F de Groot, Danielle Cohen, Joan B Heijns, et al.
Pageof 13

Showing results (111-120 of 127) with videos related to

Sort By:
Pageof 13
NPJ Breast Cancer|January 22, 2025
Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionalityNoor A M Bakker, Hannah Garner, Ewald van Dyk, et al.
Journal of Sex & Marital Therapy|November 26, 2019
Sexual Health Needs: How Do Breast Cancer Patients and Their Partners Want Information?L F Albers, G F Van Ek, E M Krouwel, et al.
Breast Care (Basel, Switzerland)|January 28, 2022
Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01)Annelot G J van Rossum, Ingrid A M Mandjes, Erik van Werkhoven, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2018
Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)A G J van Rossum, M Kok, E van Werkhoven, et al.
Oncotarget|January 27, 2018
Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapyAnnelot G J van Rossum, Marleen Kok, Danielle McCool, et al.
Cell Reports|April 6, 2022
FER regulates endosomal recycling and is a predictor for adjuvant taxane benefit in breast cancerSandra Tavares, Nalan Liv, Milena Pasolli, et al.
Ultramicroscopy|November 19, 2011
Interlaboratory round robin on cantilever calibration for AFM force spectroscopyJoost te Riet, Allard J Katan, Christian Rankl, et al.
Journal of Bacteriology|July 12, 2011
Genome sequences of Alicycliphilus denitrificans strains BC and K601TMargreet J Oosterkamp, Teun Veuskens, Caroline M Plugge, et al.
Cancer Research|January 15, 2016
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB TrialLale Erdem-Eraslan, Martin J van den Bent, Youri Hoogstrate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2025
Ribociclib-letrozole combination as an alternative for neoadjuvant chemotherapy in selected post-menopausal patients with luminal breast cancer (BOOG 2017-01)Anne F de Groot, Danielle Cohen, Joan B Heijns, et al.
Pageof 13